MINOCIN (minocycline hydrochloride) by Pfizer is clinical pharmacology following a single dose of minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2. Approved for infections caused by the following gram-negative bacteria, infections caused by the following gram-positive bacteria, the treatment of the following infections due to susceptible isolates of the designated bacteria: rocky mountain spotted fever and 5 more indications.
Drug data last refreshed 1mo ago
CLINICAL PHARMACOLOGY Following a single dose of Minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2.52 to 6.63 mcg/mL (average 4.18 mcg/mL) at the end of infusion and 0.82 to 2.64 mcg/mL (average 1.38 mcg/mL) after 12 hours. In a…
Worked on MINOCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel